Diabetes Dialogue: ATTD 2024 Preview

Published on: 

Hosts break down their favorite sessions at the upcoming 17th International Conference on Advanced Technologies and Treatments for Diabetes.

Few fields can claim to have embraced the evolving role of technology in patient care as diabetes management. Nowhere is this desire to improve care and quality of life for patients more evident than at the International Conference on Advanced Technologies and Treatments for Diabetes. The excitement surrounding the meeting and the sheer number of attendees continues to grow annually as the 17th iteration of the meeting approaches in early March.

Among the attendees and fervent supporters of the meeting are Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center. Leading into the premier diabetes technology meeting of the year, Isaacs and Bellini sat down for a special episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives.

In the episode, hosts provide insight into sessions to watch, device news they are excited for, what makes ATTD a unique and valuable experience for the diabetes care team, and how the meeting’s annual yearbook session encapsulates the exciting developments within the field.

Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.